clinical trial · NCT05572684
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors
Advanced or Metastatic Solid TumorsMicrosatellite Instability LowMicrosatellite Instability HighMicrosatellite StableOvarian CancerGastric CancerColo-rectal CancerEsophageal CancerNC410pembrolizumab
brief summary
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors
started
Oct 6, 2022
primary completion
Jul 1, 2025
completion
Nov 1, 2025
last updated
Dec 16, 2024
official title
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants with Advanced Unresectable And/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol